Mycoplasmal Contamination And Its Impact On The Biopharma Industry

Source: Bionique Testing Laboratories, Inc.

A Q&A With Daniel Lundin, Founder, President, and CEO of Bionique Testing Laboratories, Inc.

Daniel Lundin has over 35 years of experience in cell biology. Since 1990, he has served as president of Bionique Testing Laboratories, an independent contract biotechnology firm specializing in the testing of cell cultures, biologicals, vaccines, and media/sera for mycoplasmal contamination. From 1984 through 1990, he was director of technical services for Bionique Laboratories (the predecessor to Bionique Testing Laboratories).

Prior to joining Bionique, Lundin was laboratory supervisor at W. Alton Jones Cell Science Center, where he participated in the coordination of the cell and tissue culture courses. Outside of the company, Lundin engages in economic development and strategic planning activities directed towards developing and attracting science and technology firms within the Adirondack Park in upstate New York.

In this Q&A, Lundin shares his insights on mycoplasma and its role in the biotechnology and pharmaceutical industries.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online